Inflammatory bowel disease: A new assessment

Scandinavian Journal of Gastroenterology, Supplement

Volumn 31, Issue 220, 1996, Pages 83-86

  Gitnick, G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's disease; Ileitis; Inflammation; Mycobacteria; Rodent models; Ulcerative colitis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; AZATHIOPRINE; BUDESONIDE; CLOFAZIMINE; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; ETHAMBUTOL; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NICOTINE; PLACEBO; PREDNISOLONE;

CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; CROHN DISEASE; DOSE RESPONSE; ENTERITIS; HUMAN; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM PARATUBERCULOSIS; ORAL DRUG ADMINISTRATION; OSTEOPENIA; PRIORITY JOURNAL; PROCTOCOLECTOMY; TRANSDERMAL DRUG ADMINISTRATION; ULCERATIVE COLITIS; PATHOPHYSIOLOGY; REVIEW;

HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 0030338040     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529609094756     Document Type: Conference Paper

References (26)

1. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994;107:532-6.
2. Ward M. The pathogenesis of Crohn's disease. Lancet 1977;2:903-5.
3. Dell'Isola B, Poyart C, Goulet O, et al. Detection of Mycobacterium paratuberculosis by polymerase chain reaction in children with Crohn's disease. J Infect Dis 1994;169:449-51.
4. Stainsby KJ, Lowes JR, Allan RN. Antibodies in Mycobacterium paratuberculosis and nine species of environmental mycobacteria in Crohn's disease and control subjects. Gut 1993;34:371-4.
5. Winslet MC, Allan A, Poxon V, et al. Faecal diversion for Crohn's colitis. A model to study the role of the faecal stream in the inflammatory process. Gut 1994;35:236-42.
6. Smith MS, Wakefield AJ. Viral association with Crohn's disease. Ann Med 1993;25:557-61.
7. Rhodes J, Thomas GAO. Smoking-good or bad for inflammatory bowel disease? Gastroenterology 1994;106:807-10.
8. Wakefield AJ, Sawyerr AM, Dhillon AP, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989;2:1057-62.
9. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Co-operative Study Group. Gastroenterology 1995;108:345-9.
10. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
11. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994:331:836-41.
12. Nygaard K, Bergan T, Bjorneklett A, Hoverstad T, Lassen J, Aase S. Topical metronidazole treatment in pouchitis. Scand J Gastroenterol 1994;29:462-7.
13. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
14. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994;39:374-80.
15. Campieri M, Paoluzi P, D'Albasio G, Brunetti G, Pera A, Barbara L. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis: a multicenter comparative trial with 5-ASA enema. Dig Dis Sci 1993;38:1843-50.
16. Yamaguchi T, Sasaki K, Kurosaki Y, Nakayama T, Kimura T. Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicyclic acid. J Drug Target 1994;2:123-31.
17. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513-8.
18. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994;330:811-5.
19. Moody GA, Mayberry JF. Perceived sexual dysfunction amongst patients with inflammatory bowel disease. Digestion 1993;54:256-60.
20. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934-44.
21. Redston MS, Papadopoulos N, Caldas C, Kinzler KW, Kern SE. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 1995;108:383-92.
22. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis at diagnosis. Gastroenterology 1994;107:1031-9.
23. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995;108:417-22.
24. McIntyre PB, Pemberton JH, Wolff BG, Beart RW, Dozois RR. Comparing functional results one year and ten years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Dis Colon Rectum 1994;37:303-7.
25. Jorge JM, Wexner SD, Morgado PJ Jr, James K, Nogueras JJ, Jagelman DG. Optimization of sphincter function after the ileoanal reservoir procedure. A prospective, randomized trial. Dis Colon Rectum 1994;37:419-23.
26. Nagel E, Bartels M, Pichlmayr R. Scanning electron-microscopic lesions in Crohn's disease: relevance for the interpretation of postoperative recurrence. Gastroenterology 1995;108:376-82.